Dublin, Dec. 15, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering.
Drug delivery remains a challenge in management of cancer
The market value of drug delivery technologies and the anticancer drugs are difficult to separate. Cancer market estimates from 2015-2025 are given according to organs involved and the types of cancer as well as according to technologies. Distribution of the into major regions is also described.
Profiles of 230 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 269 collaborations. The bibliography contains over 650 publications that are cited in the report.The report is supplemented with 66 tables and 12 figures.
Several innovative methods of drug delivery are used in cancer. These include use of microparticles as carriers of anticancer agents. These may be injected into the arterial circulation and guided to the tumor by magnetic field for targeted drug delivery. Polyethylene glycol (PEG) technology has been used to overcome some of the barriers to anticancer drug delivery. Encapsulating anticancer drugs in liposomes enables targeted drug delivery to tumor tissues and prevents damage to the normal surrounding tissues. Monoclonal antibodies can be used for the delivery of anticancer payloads such as radionucleotides, toxins and chemotherapeutic agents to the tumors.
Drug delivery strategies vary according to the type and location of cancer. Role of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical. Biodegradable implants of carmustine are already used in the treatment of malignant brain tumors.
Key Topics Covered:
Part I: Technologies & Markets
Executive Summary
1. Introduction to cancer therapy
2. Innovative treatments for cancer
3. Drug delivery systems for cancer
4. Delivery of Biological Therapies for Cancer
5. Delivery strategies according to cancer type and location
6. Cancer drug delivery markets
7. References
Part II: Companies
8. Companies involved in cancer drug delivery
For more information about this report visit http://www.researchandmarkets.com/research/l7532z/drug_delivery_in
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Delivery, Oncology Drugs


TSMC Japan's Second Fab to Produce 3nm Chips by 2028
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 



